0001209191-19-045822.txt : 20190813 0001209191-19-045822.hdr.sgml : 20190813 20190813195729 ACCESSION NUMBER: 0001209191-19-045822 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190813 FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taylor Michael Douglas CENTRAL INDEX KEY: 0001494875 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 191022419 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC STREET 2: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-08-13 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001494875 Taylor Michael Douglas C/O DECIPHERA PHARMACEUTICALS, INC. 500 TOTTEN POND ROAD WALTHAM MA 02451 1 0 0 0 Common Stock 2019-08-13 4 M 0 22500 1.89 A 22500 D Common Stock 2019-08-13 4 S 0 3433 39.4704 D 19067 D Common Stock 2019-08-13 4 S 0 13767 40.4996 D 5300 D Common Stock 2019-08-13 4 S 0 1300 41.7718 D 4000 D Common Stock 2019-08-13 4 S 0 4000 42.4946 D 0 D Stock Option (Right to Buy) 1.89 2019-08-13 4 M 0 22500 0.00 D 2025-12-17 Common Stock 22500 517135 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.03, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.14 to $41.10, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.22 to $42.13, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.27 to $42.90, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of March 1, 2014, subject to continued service through such dates. /s/ Thomas P. Kelly, Attorney-in-Fact 2019-08-13